Evaluation of Immunotherapy in the Treatment of Melanoma

Surgical Oncology Clinics of North America

Volumn 15, Issue 2, 2006, Pages 399-418

  Faries, Mark B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA INTERFERON; CANVAXIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; FREUND ADJUVANT; GANGLIOSIDE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; M VAX; MELACINE; MELAN A; MONOPHENOL MONOOXYGENASE; PEPTIDE DERIVATIVE; QS 21; TAMOXIFEN; TEMOZOLOMIDE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; VACCINIA ONCOLYSATE;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGEN PURIFICATION; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EFFECTOR CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INNATE IMMUNITY; LOW DRUG DOSE; MELANOGENESIS; MELANOMA; MYELOABLATIVE CONDITIONING; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; MELANOMA; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; SKIN NEOPLASMS;

EID: 33646033135     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2005.12.008     Document Type: Review

References (77)

1. Bodurtha A., Berkelhammer J., Kim Y., et al. A clinical histologic and immunologic study of a case of metastatic melanoma undergoing spontaneous remission. Cancer 37 2 (1976) 735-742
2. Tuthill R., Unger J., Liu P., et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118 4 (2002) 504-511
3. Clark Jr. W.J., Elder D.E., Guerry IV D., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81 24 (1989) 1893-1904
4. Kruper L., Botbyl J., Czerniecki B., et al. Predicting sentinel lymph node status in stage I/II melanoma. [abstract]. Proc Am Soc Clin Oncol 23 (2005) 710s Abstract 7501
5. Giuliano A., Moseley H., Irie R., et al. Immunologic aspects of unknown primary melanoma. Surgery 87 1 (1980) 101-105
6. Anbari K., Schuchter L., Bucky L., et al. Melanoma of unknown primary site: presentation, treatment and prognosis-a single institution study. Cancer 79 9 (1997) 1816-1821
7. Giuliano A., Cochran A., and Morton D. Clinical aspects of unknown primary melanoma. Ann Surg 191 1 (1980) 98-104
8. Morton D., Wanek L., Nizze J., et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214 4 (1991) 491-499
9. Hsueh E., Gupta R., Yee R., et al. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?. Ann Surg Oncol 7 (2000) 232
10. King M., Spooner D., and Rowlands D. Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: a case report and a review of the literature. Clin Oncol (R Coll Radiol) 13 6 (2001) 466-469
11. Wang T.S., Lowe L., Smith II J.W., et al. Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg 24 8 (1998) 915-919
12. Nathanson. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 44 (1976) 67-76
13. Bulkley G., Cohen M., Banks P., et al. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile. Cancer 36 2 (1975) 485-494
14. Peterson R., Kelley W., and Good R. Ataxia-telangiectasia: Its association with a defective thymus, immunological-deficiency disease and malignancy. Lancet 1 (1964) 1189-1193
15. Smith C., Lilly S., Mann L., et al. AIDS-related malignancies. Ann Med 30 4 (1998) 323-344
16. Penn I., and Starzl T. Malignant lymphomas in transplantation patients: a review of the world experience. Int Z Klin Pharmakol Ther Toxikol 3 (1998) 49-54
17. Rodriguez L., Klencke B., Vin-Christian K., et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 138 6 (2002) 765-770
18. Morton D., Ollila D., Hsueh E., et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 49 2 (1999) 101-116
19. Ollila D., and Morton D. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am 8 1 (1998) 183-196
20. Mackie R., Reid R., and Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 34 6 (2003) 567-568
21. Nasi M., Meyers M., Livingston P., et al. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 7 Suppl 2 (1997) S155-S162
22. Vadhan-Raj S., Cordon-Cardo C., Carswell E., et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6 10 (1988) 1636-1648
23. Cascinelli N., Rumke P., MacKie R., et al. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 28 (1989) 282-286
24. Eilber F., Morton D., Holmes E., et al. Adjuvant immunotherapy with BCG in treatment of regional lymph node metastases from malignant melanoma. N Engl J Med 294 5 (1976) 237-240
25. Morton D., Eilber F., Malmgren R., et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68 (1970) 158
26. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 5038 (1991) 1643-1647
27. Kawakami Y., Eliyahu S., Delgado C., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91 (1994) 6458-6462
28. Busam K., Chen Y., Old L., et al. Expression of melan-A (MART-1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Path 22 (1998) 976-982
29. Riker A., Cormier J., Panelli M., et al. Immune selection following antigen specific immunotherapy of melanoma. Surgery 126 2 (1999) 112-120
30. Chianese-Bullock K., Pressley J., Garbee C., et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174 5 (2005) 3080-3086
31. Zeng G., Wang X., Robbins P., et al. CD4 + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA-DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98 7 (2001) 3964-3969
32. Heath W., and Carbone F. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1 2 (2001) 126-134
33. Eilber F., and Morton D. Sarcoma-specific antigens: detection by complement fixation with serum from sarcoma patients. J Natl Cancer Inst 44 3 (1970) 651-656
34. Berd D., Maguire H., Schuchter L., et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15 6 (1997) 2359-2370
35. Rosenberg S., and Rapp H. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60 3 (1976) 419-430
36. Mastrangelo M., Bellet R., Berkelhammer J., et al. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36 4 (1975) 1305-1308
37. vonWussow P., Block B., Hartmann F., et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61 6 (1988) 1071-1074
38. Paul E., Muller I., Renner H., et al. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional B-interferon injection. Melanoma Res 13 6 (2003) 611-617
39. Ridolfi L., and Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 49 44 (2002) 335-339
40. Ridolfi L., Ridolfi R., Ascari-Raccagni A., et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 15 3 (2001) 218-223
41. Si Z., Hersey P., and Coates A. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6 3 (1996) 247-255
42. Keilholz U., and Eggermont A. The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. Oncology 58 2 (2000) 89-95
43. Atkins M., Lotze M., Dutcher J., et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 7 (1999) 2105-2116
44. Rosenberg S., Yang J., White D., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 3 (1998) 307-319
45. Mughal T., Thomas M., and Robinson W. Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology 48 5 (1991) 365-368
46. Kirkwood J., Ibrahim J., Sondak V., et al. High and low dose interferon alpha-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 12 (2000) 2444-2458
47. Kirkwood J., Manola J., Ibrahim J., et al. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10 (2004) 1670-1677
48. Sondak V., Ross M., and Schuchter L. Early stage (I, II, III) melanoma. Curr Treat Options Oncol 2 3 (2001) 183-191
49. O'Day S., Kim C., and Reintgen D. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control 9 1 (2002) 31-38
50. O'Day S., Gammon G., Boasberg P., et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2752-2761
51. Atkins M., Lee S., Flaherty L., et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2, interferon-alpha-2b versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. [abstract]. Proc Am Soc Clin Oncol 22 (2003) 708 Abstract 2847
52. Rosenberg S., Yannelli J., Yang J., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86 15 (1994) 1159-1166
53. Goedegebuure P., Douville L., Li H., et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13 8 (1995) 1939-1949
54. Dudley M., Wunderlich J., Yang J., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 10 (2005) 2346-2357
55. Salgaller M., Marincola F., Cormier J., et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56 20 (1996) 4749-4757
56. Jager E., Ringhoffer M., Dienes H., et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67 1 (1996) 54-62
57. Jager E., Ringhoffer M., Altmannsberger M., et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71 (1997) 142
58. Rosenberg S., Yang J., Schwartzentruber D., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 3 (1998) 321-327
59. Nestle F., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 4 3 (1998) 269-270
60. Bedrosian I., Mick R., Xu S., et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21 20 (2003) 3826-3835
61. Schadendorf D., Nestle F., Broecker E., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells as first-line treatment of patients with metastatic melanoma: results of a prospective-randomized phase III study. Proc Am Soc of Clin Oncol 23 (2004) 709
62. Bystryn J., Zeleniuch-Jacquotte A., Oratz R., et al. Double-blind trial of a polyvalent, shed-antigen melanoma vaccine. Clin Cancer Res 7 (2001) 1882
63. Ravindranath M., Bauer P., Cornillez-Ty C., et al. Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. J Immunol Methods 197 1-2 (1996) 51-67
64. Ravindranath M., Morton D., and Irie R. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49 14 (1989) 3891-3897
65. Kirkwood J., Ibrahim J., Sosman J., et al. High-dose interferon alpha 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine patients with resected stage IIB-III melanoma: results of intergoup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370
66. Wallack M., Scoggin S., and Sivanandham M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med 59 3 (1992) 227-233
67. Wallack M., Sivanandham M., Balch C., et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187 1 (1998) 69-77
68. Hersey P., Coates A., McCarthy W., et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20 (2002) 4148-4190
69. Sondak V., Liu P., Tuthill R., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 (2002) 2058-2066
70. Mitchell M. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25 6 (1998) 623-635
71. Sosman J., Unger J., Liu P., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20 8 (2002) 2067-2075
72. Berd D., Sato T., Maguire H., et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22 3 (2004) 403-415
73. Faries M., and Morton D. Melanoma: Is immunotherapy of benefit?. Adv Surg 37 (2003) 139-169
74. Morton D., Foshag L., Hoon D., et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216 4 (1992) 463-482
75. Hsueh E., Gupta R., Qi K., and Morton D. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16 9 (1998) 2913-2920
76. DiFronzo L., Gupta R., Essner R., et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20 (2002) 3242
77. Chung M., Gupta R., Hsueh E., et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 21 2 (2003) 313-319